KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Non Operating Income (2016 - 2026)

TherapeuticsMD filings provide 17 years of Non Operating Income readings, the most recent being $826000.0 for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 34.75% to $826000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $4.0 million, a 8.1% increase, with the full-year FY2025 number at $3.7 million, down 0.85% from a year prior.
  • Non Operating Income hit $826000.0 in Q1 2026 for TherapeuticsMD, down from $972000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.7 million in Q2 2024 to a low of -$22.8 million in Q1 2022.
  • Median Non Operating Income over the past 5 years was $357000.0 (2023), compared with a mean of -$834764.7.
  • Biggest five-year swings in Non Operating Income: tumbled 125.55% in 2022 and later surged 2898.28% in 2024.
  • TherapeuticsMD's Non Operating Income stood at $11000.0 in 2022, then surged by 145.45% to $27000.0 in 2023, then surged by 2622.22% to $735000.0 in 2024, then skyrocketed by 32.24% to $972000.0 in 2025, then fell by 15.02% to $826000.0 in 2026.
  • The last three reported values for Non Operating Income were $826000.0 (Q1 2026), $972000.0 (Q4 2025), and $912000.0 (Q3 2025) per Business Quant data.